文献速递哮喘

激素避孕与重度哮喘急性发作风险:17年人群队列研究

Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study.
PubMed 文献 · Thorax · 2020-11-23

结果显示,既往或当前使用任何激素避孕药及复方避孕药与重度急性发作风险降低相关,且使用时间越长风险越低,但仅孕激素避孕药无此关联。

要点

  • 激素避孕药使用与重度哮喘急性发作风险降低相关。
  • 复方避孕药及较长使用时间与风险降低相关,仅孕激素避孕药无关联。
  • 仍需机制研究解释激素避孕药对哮喘临床结局的影响。

核心结论

  • 在育龄期哮喘女性中,使用激素避孕药可能降低重度哮喘急性发作风险。

主要发现

  • 基线时34%使用任何激素避孕药,25%使用复方(雌激素/孕激素)避孕药,9%使用仅孕激素避孕药。
  • 与未使用相比,既往使用任何激素避孕药IRR 0.94(95%CI 0.92-0.97),当前使用IRR 0.96(95%CI 0.94-0.98)。
  • 既往使用复方避孕药IRR 0.92(95%CI 0.87-0.97),当前使用IRR 0.93(95%CI 0.91-0.96)。
  • 使用3-4年IRR 0.94(95%CI 0.92-0.97),5年以上IRR 0.91(95%CI 0.89-0.93)。
  • 仅孕激素避孕药使用与重度哮喘急性发作风险无显著关联。

关键数值与推荐

  • 重度哮喘急性发作定义依据欧洲呼吸学会/美国胸科学会推荐:哮喘相关住院、因哮喘急诊就诊和/或口服糖皮质激素处方。

临床怎么用

  • 对育龄期哮喘女性,处方的激素避孕药选择可考虑其与重度急性发作风险降低的关联,但需结合个体情况。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Longitudinal studies investigating impact of exogenous sex steroids on clinical outcomes of asthma in women are lacking. We investigated the association between use of hormonal contraceptives and risk of severe asthma exacerbation in reproductive-age women with asthma. METHODS: We used the Optimum Patient Care Research Database, a population-based, longitudinal, anonymised primary care database in the UK, to construct a 17-year (1 January 2000-31 December 2016) retrospective cohort of reproductive-age (16-45 years, n=83 084) women with asthma. Using Read codes, we defined use, subtypes and duration of use of hormonal contraceptives. Severe asthma exacerbation was defined according to recommendations of the European Respiratory Society/American Thoracic Society as asthma-related hospitalisation, accident and emergency department visits due to asthma and/or oral corticosteroid prescriptions. Analyses were done using multilevel mixed-effects Poisson regression with QR decomposition. RESULTS: The 17-year follow-up resulted in 456 803 person-years of follow-up time. At baseline, 34% of women were using any hormonal contraceptives, 25% combined (oestrogen/progestogen) and 9% progestogen-only contraceptives. Previous (incidence rate ratio (IRR) 0.94, 95% CI 0.92 to 0.97) and current (IRR 0.96, 95% CI 0.94 to 0.98) use of any, previous (IRR 0.92, 95% CI 0.87 to 0.97) and current use of combined (IRR 0.93, 95% CI 0.91 to 0.96) and longer duration of use (3-4 years: IRR 0.94, 95% CI 0.92 to 0.97; 5+ years: IRR 0.91, 95% CI 0.89 to 0.93) of hormonal contraceptives, but not progestogen-only contraceptives, were associated with reduced risk of severe asthma exacerbation compared with non-use. CONCLUSIONS: Use of hormonal contraceptives may reduce the risk of severe asthma exacerbation in reproductive-age women. Mechanistic studies investigating the biological basis for the influence of hormonal contraceptives on clinical outcomes of asthma in women are required. PROTOCOL REGISTRATION NUMBER: European Union electronic Register of Post-Authorisation Studies (EUPAS22967).

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Nwaru BI, Tibble H, Shah SA, et al. Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study. Thorax. 2020. PMID: 33234554. doi:10.1136/thoraxjnl-2020-215540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。